BIRC5 and neuroendocrine carcinoma: For example, terameprocol (EM1421, M4N), that disrupts the activity of transcription factor Sp1 and thereby prevents transcription of survivin, also inhibited cell proliferation of our GEP-NEC cell lines (Dizdar et al. 2017) and has been under consideration in a phase I clinical trial including patients with solid tumors (ClinicalTrials.gov Identifier: NCT00259818).